Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.06.16.545225

Epitope spreading of Lyme autoantigen apoB-100 and CD4+ T cell responses to Borrelia burgdorferi Mcp4 are regulated by IL-10 in murine Lyme disease

Abstract

Borrelia burgdorferi, the causative agent of Lyme disease (LD), has evolved immune evasion mechanisms to establish a persistent infection in their vertebrate hosts, resulting in chronic inflammation and autoimmune T and B cell reactivity in many B. burgdorferi-infected individuals. In this study, we used an unbiased immunopeptidomics approach to identify foreign and self MHC class II peptides isolated from inguinal and popliteal lymph nodes from B. burgdorferi- infected C57BL/6 (B6) mice, which develop mild, self-limiting LD; and from infected B6 Il10-/- mice, which develop severe, persistent LD. Nearly 10,000 MHC-II peptides were identified by LC-tandem MS analysis which included many peptides derived from proteins abundant in arthritic joints that are associated with inflammation, tissue repair, and extracellular matrix remodeling. Notably, the number and variety of unique peptides derived from apolipoprotein B- 100 (apoB-100); a validated autoantigen in human Lyme arthritis (LA), atherosclerosis, and liver disease; was greatly expanded in lymph nodes of infected mice, particularly in Il10-/- mice at 4 weeks (6-fold increase) and 16 weeks (15-fold increase) post-infection, compared with uninfected mice, indicating epitope spreading. One of the apoB-100 peptides identified in infected, but not uninfected, B6 and Il10-/- mice was APOB3500-3515, an immunogenic cryptic epitope in murine autoimmune atherosclerosis. No apoB-100 peptides had sequence homology to any B. burgdorferi antigens. Surprisingly, only six peptides derived from B. burgdorferi proteins were validated in this study. One of these B. burgdorferi epitopes, derived from methyl- accepting chemotaxis protein Mcp4 (BB0680), was an immunogenic target of CD4+ T cell responses in B. burgdorferi-infected Il10-/- mice, but not in B6 mice. In conclusion, this study has shed light on the importance of IL-10 in suppressing epitope spreading and limiting B. burgdorferi-specific CD4+ T cell responses. Furthermore, this study supports epitope spreading and exposure of cryptic antigens as likely mechanisms of infection-induced apoB-100 autoimmunity in LD. AUTHOR SUMMARYLyme disease is caused by infection with the spirochetal pathogen Borrelia burgdorferi, and affects [~]500,000 individuals in the U.S. annually. T cell responses to both host and pathogen are dysregulated during infection, resulting in chronic infection and frequent development of autoimmunity. To assess the immune-relevant CD4+ T cell epitopes presented during development of Lyme disease, we used an unbiased, immunopeptidomics approach to characterized the MHC class II immunopeptidome in mice infected with Borrelia burgdorferi. We identified nearly 10,000 unique peptides. Peptides derived from apoB-100, a known human Lyme autoantigen, were highly enriched in infected mice, compared with uninfected controls, and showed evidence of epitope spreading. Furthermore, we identified several peptides derived from Borrelia burgdorferi, including one immunogenic peptide from a methyl-accepting chemotaxis protein, Mcp4. Interestingly, both apoB-100 epitope spreading and immune responses to Mcp4 were observed in mice lacking the anti-inflammatory cytokine IL-10, indicating an important role of IL-10 in suppressing T cell responses to Mcp4 and epitope spreading of Lyme autoantigen apoB-100.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Danner, R., Pereckas, M., Rouse, J. R., Wahhab, A., Prochniak, L. M., Lochhead, R. B.. 2023-06-18. Epitope spreading of Lyme autoantigen apoB-100 and CD4+ T cell responses to Borrelia burgdorferi Mcp4 are regulated by IL-10 in murine Lyme disease. https://doi.org/10.1101/2023.06.16.545225

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

HIV-1 prime-boost vaccination shapes distinct clonal trajectories and memory precursor states of Env- and Gag-specific T cells

Despite decades of HIV-1 vaccine development, the clonal and cellular determinants of durable vaccine-induced T cell memory remain incompletely understood. Here, we combined antigen-specific T cell receptor (TCR) identification, longitudinal TCR sequencing, and single-cell multi-omics to characterize Env- and Gag-specific memory precursor T cells elicited by the HIV Vaccine Trials Network (HVTN) 505 DNA prime-recombinant adenovirus serotype 5 (rAd5) boost (DNA/rAd5) vaccine regimen. We developed a generalizable high-throughput approach to identify HIV-1 Env- and Gag-specific TCRs and found distinct patterns of clonal expansion, persistence, and contribution to memory between Env- and Gag-specific CD8 T cell responses. The DNA prime and rAd5 boost differentially shaped these repertoires, with rAd5-induced clones contributing proportionally more to the Gag-specific than to the Env-specific memory precursor compartment. Single-cell immune profiling further revealed distinct memory precursor states, with Env-specific responses enriched for GZMBPRF1 cytotoxic effector-memory (EM) CD8 T cells and Gag-specific responses containing a larger cycling/proliferative population. Together, these findings demonstrate that heterologous DNA/rAd5 vaccination generates antigen-specific CD8 T cell memory with distinct clonal trajectories and cellular programs, providing new insights into how vaccine platform and antigen-specificity shape the durability and functional properties of HIV-1 specific cellular immunity.

immunology↗

MicroRNA-146a Deficiency Protects NOD Mice from Autoimmune Diabetes by Enhancing c-Rel-Dependent Regulatory T Cell Function

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by T-cell mediated destruction of pancreatic islet {beta}-cells with genetic, environmental, and molecular triggers involved in disease pathogenesis. Patients with T1D have elevated serum levels of microRNA146a (miR146a). Polymorphisms in the miR146a gene that result in reduced expression of miR146a are associated with protection from T1D. We studied physiological regulators of miR146a expression and found that both hyperglycemia and elevated O-GlcNAcylation increased miR146a expression in T cells. Peripheral blood mononuclear cells (PBMCs) from T1D patients showed increased miR146a and O-GlcNAc transferase (OGT) expression, suggesting increased O-GlcNAcylation may promote miR146a expression in T1D patients. To determine the genetic and developmental role of miR146a in T1D, we generated miR146a-knockout (KO) non-obese diabetic (NOD) mice and found that absence of miR146a significantly protected NOD mice from spontaneous autoimmune diabetes. While we found no impact of miR146a knockout on general hematopoietic parameters and immune cell populations, remarkably, immune cell infiltration into the pancreas was significantly attenuated. Protection from autoimmune diabetes in miR146a-KO NOD mice was associated with increased regulatory T (Treg) cells in the spleen and pancreatic lymph node. Mechanistically, absence of miR146a increased NF-{kappa}B c-Rel expression in Treg cells and enhanced c-Rel binding at the Forkhead box protein P3 (FOXP3) promoter, which positively regulated Treg cell development and suppressor function, offering protection from T1D in miR146a-KO NOD mice. Our findings reveal miR146a as a key regulator of Treg cell-mediated immune tolerance through controlling NF-{kappa}B c-Rel-dependent FOXP3 expression and suggest targeting miR146a as a potential strategy to restore peripheral tolerance in T1D.

immunology↗

Patient-Derived Melanoma Organoids Preserve Tumor-Immune Heterogeneity and Reveal Context-Dependent Responses to Immune Checkpoint Blockade

Abstract Background: Experimental models that retain endogenous tumor immune complexity are needed to investigate heterogeneous responses to immune checkpoint inhibitors (ICIs) in melanoma. We established patient-derived melanoma organoids (PDMOs) to examine retention of parental tumor cellular components and investigate patient-specific and context-dependent responses to checkpoint blockade. Methods: Fresh melanoma specimens (n=50), including primary tumors, neoadjuvant-treated tumors and tumor-infiltrating lymphocyte (TIL) associated samples were processed for Matrigel-embedded culture of patient-derived melanoma organoids (PDMOs). Characterization and functional studies were performed in subsets of established cultures. Immunofluorescence assessed tumor, stromal, immune, and checkpoint-marker expression in PDMOs and matched parental tissues. NGFR expression was evaluated in relation to organoid establishment and growth. Responses to anti PD1 alone or combined with anti-LAG3 or anti-CTLA4 therapies were evaluated using viability and morphological analyses, with selected models undergoing immune phenotyping and multiplex cytokine profiling. Available clinical outcomes were used for exploratory comparison. PDMOs and matched two-dimensional cultures were evaluated under 21% and 5% oxygen conditions. Results: PDMOs were established from 30 of 50 specimens (60%) and retained melanoma, stromal, lymphoid, and myeloid components identified in matched parental tissues during early culture, together with immune checkpoint expression. Higher NGFR (CD271) expression was associated with greater organoid-forming capacity in an exploratory subset. Responses to checkpoint blockade varied across patient-derived models and regimens, with combination blockade not uniformly producing lower viability than PD1 monotherapy. Ex vivo responses showed parallels with available clinical outcomes, with discordant cases also observed. In three selected PDMOs, divergent PD-1 responses were accompanied by differences in T-cell and myeloid representation, MHCII and AXL expression, and inflammatory versus immunoregulatory cytokine profiles. Under normoxic conditions, PDMOs and matched two-dimensional cultures exhibited divergent treatment sensitivities, including clinically responding cases in which sensitivity was retained in PDMOs but attenuated in monolayers. Changing oxygen tension further altered checkpoint sensitivity within individual PDMOs, with the direction and magnitude of the observed shifts varying by model and regimen. Conclusions: Early passage PDMOs retain key endogenous tumor, immune, and stromal components and support functional investigation of patient-derived melanoma biology. Their heterogenous responses across checkpoint regimens and oxygen conditions provide a platform for investigating how tumor-immune composition and environmental context influence treatment sensitivity.

immunology↗